{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T20:45:11Z","timestamp":1790196311524,"version":"4.1.0"},"reference-count":132,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2021,4,28]],"date-time":"2021-04-28T00:00:00Z","timestamp":1619568000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2021,4,28]],"date-time":"2021-04-28T00:00:00Z","timestamp":1619568000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100000265","name":"Medical Research Council","doi-asserted-by":"publisher","award":["MR\/P018904\/1"],"award-info":[{"award-number":["MR\/P018904\/1"]}],"id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000764","name":"Kings College London","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000764","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000272","name":"National Institute for Health Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Rheumatol Rep"],"published-print":{"date-parts":[[2021,6]]},"DOI":"10.1007\/s11926-021-01005-x","type":"journal-article","created":{"date-parts":[[2021,4,28]],"date-time":"2021-04-28T16:28:44Z","timestamp":1619627324000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Drivers of Inflammation in Psoriatic Arthritis: the Old and the New"],"prefix":"10.1007","volume":"23","author":[{"given":"Charlotte","family":"O\u2019Brien-Gore","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth H.","family":"Gray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucy E.","family":"Durham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonie S.","family":"Taams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5110-3320","authenticated-orcid":false,"given":"Bruce W.","family":"Kirkham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,4,28]]},"reference":[{"key":"1005_CR1","doi-asserted-by":"publisher","first-page":"e000656","DOI":"10.1136\/rmdopen-2018-000656","volume":"4","author":"JF Merola","year":"2018","unstructured":"Merola JF, Espinoza LR, Fleischmann R. Distinguishing rheumatoid arthritis from psoriatic arthritis. RMD Open. 2018;4:e000656.","journal-title":"RMD Open"},{"key":"1005_CR2","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1056\/NEJMra1505557","volume":"376","author":"CT Ritchlin","year":"2017","unstructured":"Ritchlin CT, Colbert RA, Gladman DD. Psoriatic arthritis. N Engl J Med. 2017;376:957\u201370.","journal-title":"N Engl J Med"},{"key":"1005_CR3","doi-asserted-by":"publisher","first-page":"i4","DOI":"10.1093\/rheumatology\/kez325","volume":"59","author":"R Winchester","year":"2020","unstructured":"Winchester R, FitzGerald O. The many faces of psoriatic arthritis: their genetic determinism. Rheumatology. 2020;59:i4\u20139.","journal-title":"Rheumatology"},{"key":"1005_CR4","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1038\/s41584-018-0044-2","volume":"14","author":"LS Taams","year":"2018","unstructured":"Taams LS, Steel KJA, Srenathan U, Burns LA, Kirkham BW. IL-17 in the immunopathogenesis of spondyloarthritis. Nat Rev Rheumatol. 2018;14:453\u201366.","journal-title":"Nat Rev Rheumatol"},{"key":"1005_CR5","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1136\/annrheumdis-2019-215356","volume":"78","author":"DG McGonagle","year":"2019","unstructured":"McGonagle DG, McInnes IB, Kirkham BW, Sherlock J, Moots R. The role of IL-17A in axial spondyloarthritis and psoriatic arthritis: recent advances and controversies. Ann Rheum Dis. 2019;78:1167\u201378.","journal-title":"Ann Rheum Dis"},{"key":"1005_CR6","doi-asserted-by":"crossref","unstructured":"Gaffen SL, Jain R, Garg AV, Cua DJ. The IL-3\u2013IL-17 immune axis: from mechanisms to therapeutic testing. Nat Rev Immunol. 2014;14:585\u2013600.","DOI":"10.1038\/nri3707"},{"key":"1005_CR7","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.jaad.2018.02.027","volume":"79","author":"AM Loos","year":"2018","unstructured":"Loos AM, et al. Comparative effectiveness of targeted immunomodulators for the treatment of moderate-to-severe plaque psoriasis: a systematic review and network meta-analysis. J Am Acad Dermatol. 2018;79:135\u2013144.e7.","journal-title":"J Am Acad Dermatol"},{"key":"1005_CR8","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1038\/ni.1736","volume":"10","author":"W O\u2019Connor Jr","year":"2009","unstructured":"O\u2019Connor W Jr, et al. A protective function for interleukin 17A in T cell\u2013mediated intestinal inflammation. Nat Immunol. 2009;10:603\u20139.","journal-title":"Nat Immunol"},{"key":"1005_CR9","doi-asserted-by":"crossref","unstructured":"Wedebye Schmidt EG, Larsen HL, Kristensen NN, Poulsen SS, Lynge Pedersen AM, Claesson MH, et al. TH17 cell induction and effects of IL-17A and IL-17F blockade in experimental colitis. Inflamm Bowel Dis. 2013;19:1567\u201376.","DOI":"10.1097\/MIB.0b013e318286fa1c"},{"key":"1005_CR10","doi-asserted-by":"crossref","unstructured":"Hueber W, Sands BE, Lewitzky S, Vandemeulebroecke M, Reinisch W, Higgins PDR, et al. Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn\u2019s disease: unexpected results of a randomised, double-blind placebo-controlled trial. Gut. 2012;61:1693\u2013700.","DOI":"10.1136\/gutjnl-2011-301668"},{"key":"1005_CR11","doi-asserted-by":"crossref","unstructured":"Targan SR, Feagan B, Vermeire S, Panaccione R, Melmed GY, Landers C, et al. A randomized, double-blind, placebo-controlled phase 2 study of brodalumab in patients with moderate-to-severe Crohn\u2019s disease. Am J Gastroenterol. 2016;111:1599\u2013607.","DOI":"10.1038\/ajg.2016.298"},{"key":"1005_CR12","doi-asserted-by":"crossref","unstructured":"Sandborn WJ, Gasink C, Gao LL, Blank MA, Johanns J, Guzzo C, et al. Ustekinumab induction and maintenance therapy in refractory Crohn\u2019s disease. N Engl J Med. 2012;367:1519\u201328.","DOI":"10.1056\/NEJMoa1203572"},{"key":"1005_CR13","doi-asserted-by":"crossref","unstructured":"Feagan BG, Pan\u00e9s J, Ferrante M, Kaser A, D'Haens GR, Sandborn WJ, et al. Risankizumab in patients with moderate to severe Crohn\u2019s disease: an open-label extension study. Lancet Gastroenterol Hepatol. 2018;3:671\u201380.","DOI":"10.1016\/S2468-1253(18)30233-4"},{"key":"1005_CR14","doi-asserted-by":"crossref","unstructured":"Ritchlin C, Rahman P, Kavanaugh A, McInnes IB, Puig L, Li S, et al. Efficacy and safety of the anti-IL-12\/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phase 3, m. Ann Rheum Dis. 2014;73:990\u20139.","DOI":"10.1136\/annrheumdis-2013-204655"},{"key":"1005_CR15","doi-asserted-by":"crossref","unstructured":"Kavanaugh A, Ritchlin C, Rahman P, Puig L, Gottlieb AB, Li S, et al. Ustekinumab, an anti-IL-12\/23 p40 monoclonal antibody, inhibits radiographic progression in patients with active psoriatic arthritis: results of an integrated analysis of radiographic data from the phase 3, multicentre, randomised, double-blind, placebo-c. Ann Rheum Dis. 2014;73:1000\u20136.","DOI":"10.1136\/annrheumdis-2013-204741"},{"key":"1005_CR16","doi-asserted-by":"crossref","unstructured":"Mease PJ, Rahman P, Gottlieb AB, Kollmeier AP, Hsia EC, Xu XL, et al. Guselkumab in biologic-naive patients with active psoriatic arthritis (DISCOVER-2): a double-blind, randomised, placebo-controlled phase 3 trial. Lancet. 2020;395:1126\u201336.","DOI":"10.1016\/S0140-6736(20)30263-4"},{"key":"1005_CR17","doi-asserted-by":"crossref","unstructured":"Deodhar A, Gottlieb AB, Boehncke WH, Dong B, Wang Y, Zhuang Y, et al. Efficacy and safety of guselkumab in patients with active psoriatic arthritis: a randomised, double-blind, placebo-controlled, phase 2 study. Lancet. 2018;391:2213\u201324.","DOI":"10.1136\/annrheumdis-2018-eular.2059"},{"key":"1005_CR18","doi-asserted-by":"crossref","unstructured":"Baeten D, \u00d8stergaard M, Wei JCC, Sieper J, J\u00e4rvinen P, Tam LS, et al. Risankizumab, an IL-23 inhibitor, for ankylosing spondylitis: results of a randomised, double-blind, placebo-controlled, proof-of-concept, dose-finding phase 2 study. Ann Rheum Dis. 2018;77:1295\u2013302.","DOI":"10.1136\/annrheumdis-2018-213328"},{"key":"1005_CR19","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1136\/annrheumdis-2018-213654","volume":"78","author":"S Siebert","year":"2019","unstructured":"Siebert S, Millar NL, McInnes IB. Why did IL-23p19 inhibition fail in AS: a tale of tissues, trials or translation? Ann Rheum Dis. 2019;78:1015\u20138.","journal-title":"Ann Rheum Dis"},{"key":"1005_CR20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jaut.2015.04.006","volume":"60","author":"N Isailovic","year":"2015","unstructured":"Isailovic N, Daigo K, Mantovani A, Selmi C. Interleukin-17 and innate immunity in infections and chronic inflammation. J Autoimmun. 2015;60:1\u201311.","journal-title":"J Autoimmun"},{"key":"1005_CR21","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1097\/BOR.0b013e3283620163","volume":"25","author":"MH Al-Mossawi","year":"2013","unstructured":"Al-Mossawi MH, Ridley A, Kiedel S, Bowness P. The role of natural killer cells, gamma delta T-cells and other innate immune cells in spondyloarthritis. Curr Opin Rheumatol. 2013;25:434\u20139.","journal-title":"Curr Opin Rheumatol"},{"key":"1005_CR22","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1007\/s11926-015-0507-2","volume":"17","author":"K Venken","year":"2015","unstructured":"Venken K, Elewaut D. IL-23 responsive innate-like T cells in spondyloarthritis: the less frequent they are, the more vital they appear. Curr Rheumatol Rep. 2015;17:30.","journal-title":"Curr Rheumatol Rep"},{"key":"1005_CR23","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1038\/nri3389","volume":"13","author":"LL Lanier","year":"2013","unstructured":"Lanier LL. Shades of grey \u2014 the blurring view of innate and adaptive immunity. Nat Rev Immunol. 2013;13:73\u20134.","journal-title":"Nat Rev Immunol"},{"key":"1005_CR24","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1016\/j.jaci.2014.11.001","volume":"135","author":"F Annunziato","year":"2015","unstructured":"Annunziato F, Romagnani C, Romagnani S. The 3 major types of innate and adaptive cell-mediated effector immunity. J Allergy Clin Immunol. 2015;135:626\u201335.","journal-title":"J Allergy Clin Immunol"},{"key":"1005_CR25","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1038\/nri3384","volume":"13","author":"P Vantourout","year":"2013","unstructured":"Vantourout P, Hayday A. Six-of-the-best: unique contributions of \u03b3\u03b4 T cells to immunology. Nat Rev Immunol. 2013;13:88\u2013100.","journal-title":"Nat Rev Immunol"},{"key":"1005_CR26","doi-asserted-by":"publisher","first-page":"2221","DOI":"10.1002\/eji.201242569","volume":"42","author":"CE Sutton","year":"2012","unstructured":"Sutton CE, Mielke LA, Mills KHG. IL-17-producing \u03b3\u03b4 T cells and innate lymphoid cells. Eur J Immunol. 2012;42:2221\u201331.","journal-title":"Eur J Immunol"},{"key":"1005_CR27","doi-asserted-by":"publisher","first-page":"761","DOI":"10.3389\/fimmu.2017.00761","volume":"8","author":"M Lawand","year":"2017","unstructured":"Lawand M, D\u00e9chanet-Merville J, Dieu-Nosjean M-C. Key features of gamma-delta T-cell subsets in human diseases and their immunotherapeutic implications. Front Immunol. 2017;8:761.","journal-title":"Front Immunol"},{"key":"1005_CR28","doi-asserted-by":"crossref","unstructured":"Cai Y, Shen X, Ding C, Qi C, Li K, Li X, et al. Pivotal role of dermal IL-17-producing \u03b3\u03b4 T cells in skin inflammation. Immunity. 2011;35:596\u2013610.","DOI":"10.1016\/j.immuni.2011.08.001"},{"key":"1005_CR29","doi-asserted-by":"publisher","first-page":"6091","DOI":"10.4049\/jimmunol.1100427","volume":"186","author":"EE Gray","year":"2011","unstructured":"Gray EE, Suzuki K, Cyster JG. Cutting edge: identification of a motile IL-17\u2013producing \u03b3\u03b4 T cell population in the dermis. J Immunol. 2011;186:6091\u20135.","journal-title":"J Immunol"},{"key":"1005_CR30","unstructured":"Venken K, et al. ROR\u03b3t inhibition selectively targets IL-17 producing iNKT and \u03b3\u03b4-T cells enriched in Spondyloarthritis patients. Nat Commun. 2019;10:9 This study using new techniques shows that gamma delta and iNKT innate lymphoid cells are of a Type-17 phenotype. Using subtraction techniques, they demonstrate these cell types contribute to much of the IL-17 protein production in an in vitro model."},{"key":"1005_CR31","doi-asserted-by":"crossref","unstructured":"Kenna TJ, Davidson SI, Duan R, Bradbury LA, McFarlane J, Smith M, et al. Enrichment of circulating interleukin-17\u2013secreting interleukin-23 receptor\u2013positive \u03b3\/\u03b4 T cells in patients with active ankylosing spondylitis. Arthritis Rheum. 2012;64:1420\u20139.","DOI":"10.1002\/art.33507"},{"key":"1005_CR32","doi-asserted-by":"crossref","unstructured":"Guggino G, Ciccia F, di Liberto D, Lo Pizzo M, Ruscitti P, Cipriani P, et al. Interleukin (IL)-9\/IL-9R axis drives \u03b3\u03b4 T cells activation in psoriatic arthritis patients. Clin Exp Immunol. 2016;186:277\u201383.","DOI":"10.1111\/cei.12853"},{"key":"1005_CR33","doi-asserted-by":"crossref","unstructured":"Kessel C, Lippitz K, Weinhage T, Hinze C, Wittkowski H, Holzinger D, et al. Proinflammatory cytokine environments can drive interleukin-17 overexpression by \u03b3\/\u03b4 T cells in systemic juvenile idiopathic arthritis. Arthritis Rheumatol. 2017;69:1480\u201394.","DOI":"10.1002\/art.40099"},{"key":"1005_CR34","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/0090-1229(91)90090-W","volume":"59","author":"R Meliconi","year":"1991","unstructured":"Meliconi R, Pitzalis C, Kingsley GH, Panayi G. S. \u03b3\/\u03b4 T cells and their subpopulations in blood and synovial fluid from rheumatoid arthritis and spondyloarthritis. Clin Immunol Immunopathol. 1991;59:165\u201372.","journal-title":"Clin Immunol Immunopathol"},{"key":"1005_CR35","unstructured":"Spadaro A, Scrivo R, Moretti T, Bernardini G, Riccieri V, Taccari E, et al. Natural killer cells and \u03b3\/\u03b4 T cells in synovial fluid and in peripheral blood of patients with psoriatic arthritis. Clin Exp Rheumatol. 2004;22:389\u201394."},{"key":"1005_CR36","doi-asserted-by":"publisher","first-page":"1610","DOI":"10.3389\/fimmu.2018.01610","volume":"9","author":"\u00c9 Toussirot","year":"2018","unstructured":"Toussirot \u00c9, Laheurte C, Gaugler B, Gabriel D, Saas P. Increased IL-22- and IL-17A-producing mucosal-associated invariant T cells in the peripheral blood of patients with ankylosing spondylitis. Front Immunol. 2018;9:1610.","journal-title":"Front Immunol"},{"key":"1005_CR37","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/j.clim.2017.03.016","volume":"183","author":"AC Chowdhury","year":"2017","unstructured":"Chowdhury AC, Chaurasia S, Mishra SK, Aggarwal A, Misra R. IL-17 and IFN-\u03b3 producing NK and \u03b3\u03b4-T cells are preferentially expanded in synovial fluid of patients with reactive arthritis and undifferentiated spondyloarthritis. Clin Immunol. 2017;183:207\u201312.","journal-title":"Clin Immunol"},{"key":"1005_CR38","doi-asserted-by":"crossref","unstructured":"Kovalovsky D, Uche OU, Eladad S, Hobbs RM, Yi W, Alonzo E, et al. The BTB\u2013zinc finger transcriptional regulator PLZF controls the development of invariant natural killer T cell effector functions. Nat Immunol. 2008;9:1055\u201364.","DOI":"10.1038\/ni.1641"},{"key":"1005_CR39","doi-asserted-by":"publisher","first-page":"367","DOI":"10.3389\/fimmu.2018.00367","volume":"9","author":"D Krijgsman","year":"2018","unstructured":"Krijgsman D, Hokland M, Kuppen PJK. The role of natural killer T cells in cancer\u2014a phenotypical and functional approach. Front Immunol. 2018;9:367.","journal-title":"Front Immunol"},{"key":"1005_CR40","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1146\/annurev.immunol.25.022106.141711","volume":"25","author":"A Bendelac","year":"2007","unstructured":"Bendelac A, Savage PB, Teyton L. The biology of NKT cells. Annu Rev Immunol. 2007;25:297\u2013336.","journal-title":"Annu Rev Immunol"},{"key":"1005_CR41","doi-asserted-by":"crossref","unstructured":"Kawano T, Cui J, Koezuka Y, Toura I, Kaneko Y, Motoki K, et al. CD1d-restricted and TCR-mediated activation of V\u03b114 NKT cells by glycosylceramides. Science. 1997;278:1626\u20139.","DOI":"10.1126\/science.278.5343.1626"},{"key":"1005_CR42","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1038\/nri3369","volume":"13","author":"PJ Brennan","year":"2013","unstructured":"Brennan PJ, Brigl M, Brenner MB. Invariant natural killer T cells: an innate activation scheme linked to diverse effector functions. Nat Rev Immunol. 2013;13:101\u201317.","journal-title":"Nat Rev Immunol"},{"key":"1005_CR43","doi-asserted-by":"crossref","unstructured":"Thapa P, Manso B, Chung JY, Romera Arocha S, Xue HH, Angelo DBS\u2019, et al. The differentiation of ROR-\u03b3t expressing iNKT17 cells is orchestrated by Runx1. Sci Rep. 2017;7:7018.","DOI":"10.1038\/s41598-017-07365-8"},{"key":"1005_CR44","doi-asserted-by":"crossref","unstructured":"Moreira-Teixeira L, Resende M, Coffre M, Devergne O, Herbeuval JP, Hermine O, et al. Proinflammatory environment dictates the IL-17\u2013producing capacity of human invariant NKT cells. J Immunol. 2011;186:5758\u201365.","DOI":"10.4049\/jimmunol.1003043"},{"key":"1005_CR45","doi-asserted-by":"publisher","first-page":"805","DOI":"10.4049\/jimmunol.1201010","volume":"190","author":"M Monteiro","year":"2013","unstructured":"Monteiro M, Almeida CF, Agua-Doce A, Graca L. Induced IL-17\u2013producing invariant NKT cells require activation in presence of TGF-\u03b2 and IL-1\u03b2. J Immunol. 2013;190:805\u201311.","journal-title":"J Immunol"},{"key":"1005_CR46","doi-asserted-by":"crossref","unstructured":"Doisne J-M, Becourt C, Amniai L, Duarte N, le Luduec JB, Eberl G, et al. Skin and peripheral lymph node invariant NKT cells are mainly retinoic acid receptor-related orphan receptor \u03b3t + and respond preferentially under inflammatory conditions. J Immunol. 2009;183:2142\u20139.","DOI":"10.4049\/jimmunol.0901059"},{"key":"1005_CR47","doi-asserted-by":"publisher","first-page":"662","DOI":"10.4049\/jimmunol.1002725","volume":"186","author":"J-M Doisne","year":"2011","unstructured":"Doisne J-M, et al. Cutting edge: crucial role of IL-1 and IL-23 in the innate IL-17 response of peripheral lymph node NK1.1\u2212invariant NKT cells to bacteria. J Immunol. 2011;186:662\u20136.","journal-title":"J Immunol"},{"key":"1005_CR48","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1136\/annrheumdis-2012-eular.190","volume":"71","author":"K Venken","year":"2013","unstructured":"Venken K, et al. AB0190 Synovial fluid derived invariant natural killer T cells in chronic arthritides show an increased programmed death-1 expression and anergic phenotype. Ann Rheum Dis. 2013;71:648.","journal-title":"Ann Rheum Dis"},{"key":"1005_CR49","unstructured":"Kim T-J, Lee SJ, Cho YN, Park SC, Jin HM, Kim MJ, et al. Immune cells and bone formation in ankylosing spondylitis. Clin Exp Rheumatol. 2012;30:469\u201375."},{"key":"1005_CR50","doi-asserted-by":"crossref","unstructured":"Jacques P, Venken K, van Beneden K, Hammad H, Seeuws S, Drennan MB, et al. Invariant natural killer T cells are natural regulators of murine spondylarthritis. Arthritis Rheum. 2010;62:988\u201399.","DOI":"10.1002\/art.27324"},{"key":"1005_CR51","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1080\/14397595.2018.1483292","volume":"29","author":"HS Sun","year":"2019","unstructured":"Sun HS, Liu DX, Bai YY, Hu NW. Disease-association of different killer cell immunoglobulin-like receptors (KIR) and HLA-C gene combinations in reactive arthritis. Mod Rheumatol. 2019;29:531\u20137.","journal-title":"Mod Rheumatol"},{"key":"1005_CR52","doi-asserted-by":"crossref","unstructured":"Manasson J, Shen N, Garcia Ferrer HR, Ubeda C, Iraheta I, Heguy A, et al. Gut microbiota perturbations in reactive arthritis and postinfectious spondyloarthritis. Arthritis Rheumatol. 2018;70:242\u201354.","DOI":"10.1002\/art.40359"},{"key":"1005_CR53","doi-asserted-by":"crossref","unstructured":"Treiner E, Duban L, Bahram S, Radosavljevic M, Wanner V, Tilloy F, et al. Selection of evolutionarily conserved mucosal-associated invariant T cells by MR1. Nature. 2003;422:164\u20139.","DOI":"10.1038\/nature01433"},{"key":"1005_CR54","doi-asserted-by":"crossref","unstructured":"Dusseaux M, Martin E, Serriari N, P\u00e9guillet I, Premel V, Louis D, et al. Human MAIT cells are xenobiotic-resistant, tissue-targeted, CD161hi IL-17\u2013secreting T cells. Blood. 2011;117:1250\u20139.","DOI":"10.1182\/blood-2010-08-303339"},{"key":"1005_CR55","doi-asserted-by":"crossref","unstructured":"Corbett AJ, Eckle SBG, Birkinshaw RW, Liu L, Patel O, Mahony J, et al. T-cell activation by transitory neo-antigens derived from distinct microbial pathways. Nature. 2014;509:361\u20135.","DOI":"10.1038\/nature13160"},{"key":"1005_CR56","doi-asserted-by":"crossref","unstructured":"Lamichhane R, Schneider M, de la Harpe SM, Harrop TWR, Hannaway RF, Dearden PK, et al. TCR- or cytokine-activated CD8+ mucosal-associated invariant T cells are rapid polyfunctional effectors that can coordinate immune responses. Cell Rep. 2019;28:3061\u201376.","DOI":"10.1016\/j.celrep.2019.08.054"},{"key":"1005_CR57","doi-asserted-by":"crossref","unstructured":"Leng T, Akther HD, Hackstein CP, Powell K, King T, Friedrich M, et al. TCR and inflammatory signals tune human MAIT cells to exert specific tissue repair and effector functions. Cell Rep. 2019;28:3077\u201391.","DOI":"10.1016\/j.celrep.2019.08.050"},{"key":"1005_CR58","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.1038\/s41590-019-0444-8","volume":"20","author":"DI Godfrey","year":"2019","unstructured":"Godfrey DI, Koay H-F, McCluskey J, Gherardin NA. The biology and functional importance of MAIT cells. Nat Immunol. 2019;20:1110\u201328.","journal-title":"Nat Immunol"},{"key":"1005_CR59","doi-asserted-by":"crossref","unstructured":"Reantragoon R, Corbett AJ, Sakala IG, Gherardin NA, Furness JB, Chen Z, et al. Antigen-loaded MR1 tetramers define T cell receptor heterogeneity in mucosal-associated invariant T cells. J Exp Med. 2013;210:2305\u201320.","DOI":"10.1084\/jem.20130958"},{"key":"1005_CR60","doi-asserted-by":"crossref","unstructured":"Fernandez CS, Amarasena T, Kelleher AD, Rossjohn J, McCluskey J, Godfrey DI, et al. MAIT cells are depleted early but retain functional cytokine expression in HIV infection. Immunol Cell Biol. 2015;93:177\u201388.","DOI":"10.1038\/icb.2014.91"},{"key":"1005_CR61","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fimmu.2011.00036","volume":"2","author":"JR Fergusson","year":"2011","unstructured":"Fergusson JR, Fleming VM, Klenerman P. CD161-expressing human T cells. Front Immunol. 2011;2:1\u20137.","journal-title":"Front Immunol"},{"key":"1005_CR62","doi-asserted-by":"crossref","unstructured":"Kjer-Nielsen L, Patel O, Corbett AJ, le Nours J, Meehan B, Liu L, et al. MR1 presents microbial vitamin B metabolites to MAIT cells. Nature. 2012;491:717\u201323.","DOI":"10.1038\/nature11605"},{"key":"1005_CR63","doi-asserted-by":"crossref","unstructured":"Koay H-F, Gherardin NA, Enders A, Loh L, Mackay LK, Almeida CF, et al. A three-stage intrathymic development pathway for the mucosal-associated invariant T cell lineage. Nat Immunol. 2016;17:1300\u201311.","DOI":"10.1038\/ni.3565"},{"key":"1005_CR64","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1146\/annurev-immunol-080719-015428","volume":"38","author":"NM Provine","year":"2020","unstructured":"Provine NM, Klenerman P. MAIT cells in health and disease. Annu Rev Immunol. 2020;38:203\u201328.","journal-title":"Annu Rev Immunol"},{"key":"1005_CR65","doi-asserted-by":"crossref","unstructured":"Serriari N-E, Eoche M, Lamotte L, Lion J, Fumery M, Marcelo P, et al. Innate mucosal-associated invariant T (MAIT) cells are activated in inflammatory bowel diseases. Clin Exp Immunol. 2014;176:266\u201374.","DOI":"10.1111\/cei.12277"},{"key":"1005_CR66","doi-asserted-by":"crossref","unstructured":"Hiejima E, Kawai T, Nakase H, Tsuruyama T, Morimoto T, Yasumi T, et al. Reduced numbers and proapoptotic features of mucosal-associated invariant T cells as a characteristic finding in patients with inflammatory bowel disease. Inflamm Bowel Dis. 2015;21:1529\u201340.","DOI":"10.1097\/MIB.0000000000000397"},{"key":"1005_CR67","doi-asserted-by":"publisher","first-page":"2864","DOI":"10.1038\/jid.2014.361","volume":"134","author":"A Johnston","year":"2014","unstructured":"Johnston A, Gudjonsson JE. Psoriasis and the MAITing game: a role for IL-17A+ invariant TCR CD8+ T cells in psoriasis? J Invest Dermatol. 2014;134:2864\u20136.","journal-title":"J Invest Dermatol"},{"key":"1005_CR68","doi-asserted-by":"crossref","unstructured":"Teunissen MBM, Yeremenko NG, Baeten DLP, Chielie S, Spuls PI, de Rie MA, et al. The IL-17A-producing CD8+ T-cell population in psoriatic lesional skin comprises mucosa-associated invariant T cells and conventional T cells. J. Invest. Dermatol. 2014;134:2898\u2013907.","DOI":"10.1038\/jid.2014.261"},{"key":"1005_CR69","doi-asserted-by":"publisher","first-page":"2305","DOI":"10.1038\/jid.2014.216","volume":"134","author":"NL Ward","year":"2014","unstructured":"Ward NL, Umetsu DT. A new player on the psoriasis block: IL-17A- and IL-22-producing innate lymphoid cells. J. Invest. Dermatol. 2014;134:2305\u20137.","journal-title":"J. Invest. Dermatol."},{"key":"1005_CR70","doi-asserted-by":"crossref","unstructured":"Cho Y-N, Kee SJ, Kim TJ, Jin HM, Kim MJ, Jung HJ, et al. Mucosal-associated invariant T cell deficiency in systemic lupus erythematosus. J Immunol. 2014;193:3891\u2013901.","DOI":"10.4049\/jimmunol.1302701"},{"key":"1005_CR71","doi-asserted-by":"publisher","first-page":"e0121124","DOI":"10.1371\/journal.pone.0121124","volume":"10","author":"C Sugimoto","year":"2015","unstructured":"Sugimoto C, Konno T, Wakao R, Fujita H, Fujita H, Wakao H. Mucosal-associated invariant T cell is a potential marker to distinguish fibromyalgia syndrome from arthritis. PLoS One. 2015;10:e0121124.","journal-title":"PLoS One"},{"key":"1005_CR72","doi-asserted-by":"crossref","unstructured":"Hayashi E, Chiba A, Tada K, Haga K, Kitagaichi M, Nakajima S, et al. Involvement of mucosal-associated invariant T cells in ankylosing spondylitis. J Rheumatol. 2016;43:1695\u2013703.","DOI":"10.3899\/jrheum.151133"},{"key":"1005_CR73","doi-asserted-by":"crossref","unstructured":"Gracey E, Qaiyum Z, Almaghlouth I, Lawson D, Karki S, Avvaru N, et al. IL-7 primes IL-17 in mucosal-associated invariant T (MAIT) cells, which contribute to the Th17-axis in ankylosing spondylitis. Ann Rheum Dis. 2016;75:2124\u201332.","DOI":"10.1136\/annrheumdis-2015-208902"},{"key":"1005_CR74","doi-asserted-by":"publisher","first-page":"154855","DOI":"10.1016\/j.cyto.2019.154855","volume":"125","author":"SK Raychaudhuri","year":"2020","unstructured":"Raychaudhuri SK, Abria C, Mitra A, Raychaudhuri SP. Functional significance of MAIT cells in psoriatic arthritis. Cytokine. 2020;125:154855.","journal-title":"Cytokine"},{"key":"1005_CR75","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1136\/annrheumdis-2014-207201","volume":"75","author":"W Gao","year":"2016","unstructured":"Gao W, McGarry T, Orr C, McCormick J, Veale DJ, Fearon U. Tofacitinib regulates synovial inflammation in psoriatic arthritis, inhibiting STAT activation and induction of negative feedback inhibitors. Ann Rheum Dis. 2016;75:311\u20135.","journal-title":"Ann Rheum Dis"},{"key":"1005_CR76","doi-asserted-by":"crossref","unstructured":"Vivier E, Artis D, Colonna M, Diefenbach A, di Santo JP, Eberl G, et al. Innate lymphoid cells: 10 years on. Cell. 2018;174:1054\u201366.","DOI":"10.1016\/j.cell.2018.07.017"},{"key":"1005_CR77","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1038\/ni.3489","volume":"17","author":"CSN Klose","year":"2016","unstructured":"Klose CSN, Artis D. Innate lymphoid cells as regulators of immunity, inflammation and tissue homeostasis. Nat Immunol. 2016;17:765\u201374.","journal-title":"Nat Immunol"},{"key":"1005_CR78","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1038\/s41577-020-0282-9","volume":"20","author":"SM Bal","year":"2020","unstructured":"Bal SM, Golebski K, Spits H. Plasticity of innate lymphoid cell subsets. Nat Rev Immunol. 2020;20:552\u201365.","journal-title":"Nat Rev Immunol"},{"key":"1005_CR79","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.imlet.2016.07.004","volume":"179","author":"K Gronke","year":"2016","unstructured":"Gronke K, Kofoed-Nielsen M, Diefenbach A. Innate lymphoid cells, precursors and plasticity. Immunol Lett. 2016;179:9\u201318.","journal-title":"Immunol Lett"},{"key":"1005_CR80","doi-asserted-by":"crossref","unstructured":"Huang Y, Guo L, Qiu J, Chen X, Hu-Li J, Siebenlist U, et al. IL-25-responsive, lineage-negative KLRG1hi cells are multipotential \u201cinflammatory\u201d type 2 innate lymphoid cells. Nat Immunol. 2015;16:161\u20139.","DOI":"10.1038\/ni.3078"},{"key":"1005_CR81","doi-asserted-by":"crossref","unstructured":"Bernink JH, Krabbendam L, Germar K, de Jong E, Gronke K, Kofoed-Nielsen M, et al. Interleukin-12 and -23 control plasticity of CD127+ group 1 and group 3 innate lymphoid cells in the intestinal lamina propria. Immunity. 2015;43:146\u201360.","DOI":"10.1016\/j.immuni.2015.06.019"},{"key":"1005_CR82","doi-asserted-by":"publisher","first-page":"2171","DOI":"10.1002\/eji.201545598","volume":"45","author":"E Montaldo","year":"2015","unstructured":"Montaldo E, Juelke K, Romagnani C. Group 3 innate lymphoid cells (ILC3s): origin, differentiation, and plasticity in humans and mice. Eur J Immunol. 2015;45:2171\u201382.","journal-title":"Eur J Immunol"},{"key":"1005_CR83","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fimmu.2019.00676","volume":"10","author":"E Pantazi","year":"2019","unstructured":"Pantazi E, Powell N. Group 3 ILCs: peacekeepers or troublemakers? What\u2019s your gut telling you?! Front Immunol. 2019;10:1\u20138.","journal-title":"Front Immunol"},{"key":"1005_CR84","doi-asserted-by":"crossref","unstructured":"Glatzer T, Killig M, Meisig J, Ommert I, Luetke-Eversloh M, Babic M, et al. ROR\u03b3t+ innate lymphoid cells acquire a proinflammatory program upon engagement of the activating receptor NKp44. Immunity. 2013;38:1223\u201335.","DOI":"10.1016\/j.immuni.2013.05.013"},{"key":"1005_CR85","doi-asserted-by":"crossref","unstructured":"Leijten EFA, van Kempen TS, Boes M, Michels-van Amelsfort JMR, Hijnen D, Hartgring SAY, et al. Brief report: enrichment of activated group 3 innate lymphoid cells in psoriatic arthritis synovial fluid. Arthritis Rheumatol. 2015;67:2673\u20138.","DOI":"10.1002\/art.39261"},{"key":"1005_CR86","doi-asserted-by":"crossref","unstructured":"Soare A, Weber S, Maul L, Rauber S, Gheorghiu AM, Luber M, et al. Cutting edge: homeostasis of innate lymphoid cells is imbalanced in psoriatic arthritis. J Immunol. 2018;200:1249\u201354.","DOI":"10.4049\/jimmunol.1700596"},{"key":"1005_CR87","doi-asserted-by":"crossref","unstructured":"Ciccia F, Guggino G, Rizzo A, Saieva L, Peralta S, Giardina AR, et al. Type 3 innate lymphoid cells producing IL-17 and IL-22 are expanded in the gut, in the peripheral blood, synovial fluid and bone marrow of patients with ankylosing spondylitis. Ann Rheum Dis. 2015;74:1739\u201347.","DOI":"10.1136\/annrheumdis-2014-206323"},{"key":"1005_CR88","doi-asserted-by":"crossref","unstructured":"Blijdorp ICJ, Menegatti S, Mens LJJ, Sande MGH, Chen S, Hreggvidsdottir HS, et al. Expansion of interleukin-22\u2013 and granulocyte\u2013macrophage colony-stimulating factor\u2013expressing, but not interleukin-17a\u2013expressing, group 3 innate lymphoid cells in the inflamed joints of patients with spondyloarthritis. Arthritis Rheumatol. 2019;71:392\u2013402.","DOI":"10.1002\/art.40736"},{"key":"1005_CR89","doi-asserted-by":"publisher","first-page":"992","DOI":"10.1038\/s41590-019-0423-0","volume":"20","author":"JH Bernink","year":"2019","unstructured":"Bernink JH, et al. c-Kit-positive ILC2s exhibit an ILC3-like signature that may contribute to IL-17-mediated pathologies. Nat Immunol. 2019;20:992\u20131003 This study demonstrates the rigour necessary to isolate different lymphoid cell types when studying cells that make up a small precentage of the total cell numbers to achieve a clear result of innate cell function.","journal-title":"Nat Immunol"},{"key":"1005_CR90","doi-asserted-by":"crossref","unstructured":"Burns LA, Maroof A, Marshall D, Steel KJA, Lalnunhlimi S, Cole S, et al. Presence, function, and regulation of IL-17F-expressing human CD4 + T cells. Eur J Immunol. 2020;50:568\u201380.","DOI":"10.1002\/eji.201948138"},{"key":"1005_CR91","first-page":"1544","volume":"25","author":"C Ritchlin","year":"1998","unstructured":"Ritchlin C, Haas-Smith SA, Hicks D, Cappuccio J, Osterland CK, Looney RJ. Patterns of cytokine production in psoriatic synovium. J Rheumatol. 1998;25:1544\u201352.","journal-title":"J Rheumatol"},{"key":"1005_CR92","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1136\/ard.2005.050963","volume":"65","author":"AWR van Kuijk","year":"2006","unstructured":"van Kuijk AWR, Reinders-Blankert P, Smeets TJM, Dijkmans BAC, Tak PP. Detailed analysis of the cell infiltrate and the expression of mediators of synovial inflammation and joint destruction in the synovium of patients with psoriatic arthritis: implications for treatment. Ann Rheum Dis. 2006;65:1551\u20137.","journal-title":"Ann Rheum Dis"},{"key":"1005_CR93","doi-asserted-by":"crossref","unstructured":"Dolcino M, Ottria A, Barbieri A, Patuzzo G, Tinazzi E, Argentino G, et al. Gene expression profiling in peripheral blood cells and synovial membranes of patients with psoriatic arthritis. PLoS One. 2015;10:e0128262.","DOI":"10.1371\/journal.pone.0128262"},{"key":"1005_CR94","doi-asserted-by":"publisher","first-page":"5483","DOI":"10.4049\/jimmunol.155.12.5483","volume":"155","author":"Z Yao","year":"1995","unstructured":"Yao Z, et al. Human IL-17: a novel cytokine derived from T cells. J Immunol. 1995;155:5483\u20136.","journal-title":"J Immunol"},{"key":"1005_CR95","doi-asserted-by":"crossref","unstructured":"Langrish CL, Chen Y, Blumenschein WM, Mattson J, Basham B, Sedgwick JD, et al. IL-23 drives a pathogenic T cell population that induces autoimmune inflammation. J Exp Med. 2005;201:233\u201340.","DOI":"10.1084\/jem.20041257"},{"key":"1005_CR96","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/ar4317","volume":"15","author":"H Benham","year":"2013","unstructured":"Benham H, et al. Th17 and Th22 cells in psoriatic arthritis and psoriasis. Arthritis Res Ther. 2013;15:1\u201311.","journal-title":"Arthritis Res Ther"},{"key":"1005_CR97","doi-asserted-by":"crossref","unstructured":"Evans HG, Gullick NJ, Kelly S, Pitzalis C, Lord GM, Kirkham BW, et al. In vivo activated monocytes from the site of inflammation in humans specifically promote Th17 responses. Proc Natl Acad Sci. 2009;106:6232\u20137.","DOI":"10.1073\/pnas.0808144106"},{"key":"1005_CR98","doi-asserted-by":"crossref","unstructured":"Gullick NJ, Evans HG, Church LD, Jayaraj DM, Filer A, Kirkham BW, et al. Linking power doppler ultrasound to the presence of Th17 cells in the rheumatoid arthritis joint. PLoS One. 2010;5:e12516.","DOI":"10.1371\/journal.pone.0012516"},{"key":"1005_CR99","doi-asserted-by":"crossref","unstructured":"Jansen DTSL, Hameetman M, van Bergen J, Huizinga TWJ, van der Heijde D, Toes REM, et al. IL-17-producing CD4+ T cells are increased in early, active axial spondyloarthritis including patients without imaging abnormalities. Rheumatology. 2015;54:728\u201335.","DOI":"10.1093\/rheumatology\/keu382"},{"key":"1005_CR100","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1007\/s11926-015-0529-9","volume":"17","author":"LE Durham","year":"2015","unstructured":"Durham LE, Kirkham BW, Taams LS. Contribution of the IL-17 pathway to psoriasis and psoriatic arthritis. Curr Rheumatol Rep. 2015;17:55.","journal-title":"Curr Rheumatol Rep"},{"key":"1005_CR101","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.imlet.2016.05.001","volume":"178","author":"U Srenathan","year":"2016","unstructured":"Srenathan U, Steel K, Taams LS. IL-17+ CD8+ T cells: differentiation, phenotype and role in inflammatory disease. Immunol Lett. 2016;178:20\u20136.","journal-title":"Immunol Lett"},{"key":"1005_CR102","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1002\/eji.202048627","volume":"50","author":"C L\u00fcckel","year":"2020","unstructured":"L\u00fcckel C, Picard FSR, Huber M. Tc17 biology and function: novel concepts. Eur J Immunol. 2020;50:1257\u201367.","journal-title":"Eur J Immunol"},{"key":"1005_CR103","doi-asserted-by":"crossref","unstructured":"Res PCM, Piskin G, de Boer OJ, van der Loos CM, Teeling P, Bos JD, et al. Overrepresentation of IL-17A and IL-22 producing CD8 T cells in lesional skin suggests their involvement in the pathogenesis of psoriasis. PLoS One. 2010;5:e14108.","DOI":"10.1371\/journal.pone.0014108"},{"key":"1005_CR104","doi-asserted-by":"crossref","unstructured":"Menon B, Gullick NJ, Walter GJ, Rajasekhar M, Garrood T, Evans HG, et al. Interleukin-17+CD8+ T cells are enriched in the joints of patients with psoriatic arthritis and correlate with disease activity and joint damage progression. Arthritis Rheumatol. 2014;66:1272\u201381.","DOI":"10.1002\/art.38376"},{"key":"1005_CR105","doi-asserted-by":"crossref","unstructured":"Xu X, Davelaar N, Mus AM, Asmawidjaja PS, Hazes JMW, Baeten DLP, et al. Interleukin-17A is produced by CD4+ but not CD8+ T cells in synovial fluid following T cell receptor activation and regulates different inflammatory mediators compared to tumor necrosis factor in a model of psoriatic arthritis synovitis. Arthritis Rheumatol. 2020;72:1303\u201313.","DOI":"10.1002\/art.41271"},{"key":"1005_CR106","doi-asserted-by":"crossref","unstructured":"Wade SM, Canavan M, McGarry T, Low C, Wade SC, Mullan RH, et al. Association of synovial tissue polyfunctional T-cells with DAPSA in psoriatic arthritis. Ann Rheum Dis. 2019;78:350\u20134.","DOI":"10.1136\/annrheumdis-2018-214138"},{"key":"1005_CR107","doi-asserted-by":"publisher","first-page":"1566","DOI":"10.1136\/annrheumdis-2019-215349","volume":"78","author":"Z Qaiyum","year":"2019","unstructured":"Qaiyum Z, Gracey E, Yao Y, Inman RD. Integrin and transcriptomic profiles identify a distinctive synovial CD8+ T cell subpopulation in spondyloarthritis. Ann Rheum Dis. 2019;78:1566 This reference shows that new functional CD8 and CD4 cells are found at sites of diease in both AxSpa and PsA. These cells are usually polyfunctional, meaning the cells express multiple cytokines simultaneously.","journal-title":"Ann Rheum Dis"},{"key":"1005_CR108","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1002\/art.41129","volume":"72","author":"E Gracey","year":"2020","unstructured":"Gracey E, et al. Altered cytotoxicity profile of CD8+ T cells in ankylosing spondylitis. Arthritis Rheumatol. 2020;72:428\u201334 This reference shows that new functional CD8 and CD4 cells are found at sites of diease in both AxSpa and PsA. These cells are usually polyfunctional, meaning the cells express multiple cytokines simultaneously.","journal-title":"Arthritis Rheumatol"},{"key":"1005_CR109","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1002\/art.41156","volume":"72","author":"KJA Steel","year":"2020","unstructured":"Steel KJA, et al. Polyfunctional, proinflammatory, tissue-resident memory phenotype and function of synovial interleukin-17A+CD8+ T cells in psoriatic arthritis. Arthritis Rheumatol. 2020;72:435\u201347.","journal-title":"Arthritis Rheumatol"},{"key":"1005_CR110","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1146\/annurev-immunol-042617-053214","volume":"37","author":"D Masopust","year":"2019","unstructured":"Masopust D, Soerens AG. Tissue-resident T cells and other resident leukocytes. Annu Rev Immunol. 2019;37:521\u201346 This reference shows that new functional CD8 and CD4 cells are found at sites of diease in both AxSpa and PsA. These cells are usually polyfunctional, meaning the cells express multiple cytokines simultaneously.","journal-title":"Annu Rev Immunol"},{"key":"1005_CR111","doi-asserted-by":"crossref","unstructured":"Kumar BV, Ma W, Miron M, Granot T, Guyer RS, Carpenter DJ, et al. Human tissue-resident memory T cells are defined by core transcriptional and functional signatures in lymphoid and mucosal sites. Cell Rep. 2017;20:2921\u201334.","DOI":"10.1016\/j.celrep.2017.08.078"},{"key":"1005_CR112","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1126\/sciimmunol.aas9673","volume":"4","author":"PA Szabo","year":"2019","unstructured":"Szabo PA, Miron M, Farber DL. Location, location, location: tissue resident memory T cells in mice and humans. Sci Immunol. 2019;4:1\u201321.","journal-title":"Sci Immunol"},{"key":"1005_CR113","doi-asserted-by":"crossref","unstructured":"Wu T, Hu Y, Lee YT, Bouchard KR, Benechet A, Khanna K, et al. Lung-resident memory CD8 T cells (TRM ) are indispensable for optimal cross-protection against pulmonary virus infection. J Leukoc Biol. 2014;95:215\u201324.","DOI":"10.1189\/jlb.0313180"},{"key":"1005_CR114","doi-asserted-by":"crossref","unstructured":"Edwards J, Wilmott JS, Madore J, Gide TN, Quek C, Tasker A, et al. CD103 + Tumor-resident CD8 + T cells are associated with improved survival in immunotherapy-na\u00efve melanoma patients and expand significantly during anti\u2013PD-1 treatment. Clin Cancer Res. 2018;24:3036\u201345.","DOI":"10.1158\/1078-0432.CCR-17-2257"},{"key":"1005_CR115","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fimmu.2020.00896","volume":"11","author":"H Bottois","year":"2020","unstructured":"Bottois H, et al. KLRG1 and CD103 expressions define distinct intestinal tissue-resident memory CD8 T cell subsets modulated in Crohn\u2019s disease. Front Immunol. 2020;11:1\u201313.","journal-title":"Front Immunol"},{"key":"1005_CR116","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1038\/nm.3883","volume":"21","author":"CO Park","year":"2015","unstructured":"Park CO, Kupper TS. The emerging role of resident memory T cells in protective immunity and inflammatory disease. Nat Med. 2015;21:688\u201397.","journal-title":"Nat Med"},{"key":"1005_CR117","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1038\/s41423-019-0291-4","volume":"17","author":"L Chen","year":"2019","unstructured":"Chen L, Shen Z. Tissue-resident memory T cells and their biological characteristics in the recurrence of inflammatory skin disorders. Cell Mol Immunol. 2019;17:64\u201375.","journal-title":"Cell Mol Immunol"},{"key":"1005_CR118","doi-asserted-by":"crossref","unstructured":"Penkava F, Velasco-Herrera MDC, Young MD, Yager N, Nwosu LN, Pratt AG, et al. Single-cell sequencing reveals clonal expansions of pro-inflammatory synovial CD8 T cells expressing tissue-homing receptors in psoriatic arthritis. Nat Commun. 2020;11:4767.","DOI":"10.1038\/s41467-020-18513-6"},{"key":"1005_CR119","doi-asserted-by":"crossref","unstructured":"Petrelli A, Mijnheer G, van Konijnenburg DPH, van der Wal MM, Giovannone B, Mocholi E, et al. PD-1+CD8+ T cells are clonally expanding effectors in human chronic inflammation. J Clin Invest. 2018;128:4669\u201381.","DOI":"10.1172\/JCI96107"},{"key":"1005_CR120","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1111\/imr.12840","volume":"294","author":"C Bridgewood","year":"2020","unstructured":"Bridgewood C, Sharif K, Sherlock J, Watad A, McGonagle D. Interleukin-23 pathway at the enthesis: the emerging story of enthesitis in spondyloarthropathy. Immunol Rev. 2020;294:27\u201347.","journal-title":"Immunol Rev"},{"key":"1005_CR121","doi-asserted-by":"crossref","unstructured":"Bridgewood C, Watad A, Russell T, Palmer TM, Marzo-Ortega H, Khan A, et al. Identification of myeloid cells in the human enthesis as the main source of local IL-23 production. Ann Rheum Dis. 2019;78:929\u201333.","DOI":"10.1136\/annrheumdis-2018-214944"},{"key":"1005_CR122","doi-asserted-by":"crossref","unstructured":"Cuthbert RJ, Watad A, Fragkakis EM, Dunsmuir R, Loughenbury P, Khan A, et al. Evidence that tissue resident human enthesis \u03b3\u03b4T-cells can produce IL-17A independently of IL-23R transcript expression. Ann Rheum Dis. 2019;78:1559\u201365.","DOI":"10.1136\/annrheumdis-2019-215210"},{"key":"1005_CR123","doi-asserted-by":"crossref","unstructured":"Cuthbert RJ, Fragkakis EM, Dunsmuir R, Li Z, Coles M, Marzo-Ortega H, et al. Brief report: group 3 innate lymphoid cells in human enthesis. Arthritis Rheumatol. 2017;69:1816\u201322.","DOI":"10.1002\/art.40150"},{"key":"1005_CR124","doi-asserted-by":"crossref","unstructured":"Watad A, Rowe H, Russell T, Zhou Q, Anderson LK, Khan A, et al. Normal human enthesis harbours conventional CD4+ and CD8+ T cells with regulatory features and inducible IL-17A and TNF expression. Ann Rheum Dis. 2020;79:1044\u201354.","DOI":"10.1136\/annrheumdis-2020-217309"},{"key":"1005_CR125","doi-asserted-by":"crossref","unstructured":"Ciccia F, Guggino G, Ferrante A, Raimondo S, Bignone R, Rodolico V, et al. Interleukin-9 overexpression and Th9 polarization characterize the inflamed gut, the synovial tissue, and the peripheral blood of patients with psoriatic arthritis. Arthritis Rheumatol. 2016;68:1922\u201331.","DOI":"10.1002\/art.39649"},{"key":"1005_CR126","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1136\/annrheumdis-2016-209334","volume":"76","author":"SM Thorarensen","year":"2017","unstructured":"Thorarensen SM, Lu N, Ogdie A, Gelfand JM, Choi HK, Love TJ. Physical trauma recorded in primary care is associated with the onset of psoriatic arthritis among patients with psoriasis. Ann Rheum Dis. 2017;76:521\u20135.","journal-title":"Ann Rheum Dis"},{"key":"1005_CR127","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1136\/annrheumdis-2019-216631","volume":"79","author":"J Manasson","year":"2020","unstructured":"Manasson J, Blank RB, Scher JU. The microbiome in rheumatology: where are we and where should we go? Ann Rheum Dis. 2020;79:727\u201333.","journal-title":"Ann Rheum Dis"},{"key":"1005_CR128","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1097\/BOR.0000000000000569","volume":"31","author":"E Gracey","year":"2019","unstructured":"Gracey E, Dumas E, Yerushalmi M, Qaiyum Z, Inman RD, Elewaut D. The ties that bind: skin, gut and spondyloarthritis. Curr Opin Rheumatol. 2019;31:62\u20139.","journal-title":"Curr Opin Rheumatol"},{"key":"1005_CR129","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.3390\/ijms21041275","volume":"21","author":"M Furue","year":"2020","unstructured":"Furue M, Furue K, Tsuji G, Nakahara T. Interleukin-17A and keratinocytes in psoriasis. Int J Mol Sci. 2020;21:1275.","journal-title":"Int J Mol Sci"},{"key":"1005_CR130","doi-asserted-by":"crossref","unstructured":"Veale DJ, McGonagle D, McInnes IB, Krueger JG, Ritchlin CT, Elewaut D, et al. The rationale for Janus kinase inhibitors for the treatment of spondyloarthritis. Rheumatology. 2019;58:197\u2013205.","DOI":"10.1093\/rheumatology\/key070"},{"key":"1005_CR131","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1038\/nm.3260","volume":"19","author":"G Schett","year":"2013","unstructured":"Schett G, Elewaut D, McInnes IB, Dayer J-M, Neurath MF. How cytokine networks fuel inflammation: toward a cytokine-based disease taxonomy. Nat Med. 2013;19:822\u20134.","journal-title":"Nat Med"},{"key":"1005_CR132","doi-asserted-by":"publisher","unstructured":"Hammitzsch A, Lorenz G, Moog P. Impact of Janus kinase inhibition on the treatment of axial spondyloarthropathies. Front Immunol. 2020;11:591176. https:\/\/doi.org\/10.3389\/fimmu.2020.591176.","DOI":"10.3389\/fimmu.2020.591176"}],"container-title":["Current Rheumatology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11926-021-01005-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11926-021-01005-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11926-021-01005-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,25]],"date-time":"2024-01-25T11:01:12Z","timestamp":1706180472000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11926-021-01005-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,28]]},"references-count":132,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2021,6]]}},"alternative-id":["1005"],"URL":"https:\/\/doi.org\/10.1007\/s11926-021-01005-x","relation":{},"ISSN":["1523-3774","1534-6307"],"issn-type":[{"value":"1523-3774","type":"print"},{"value":"1534-6307","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,28]]},"assertion":[{"value":"23 March 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 April 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declaration"}},{"value":"LST has received speaker fees and\/or research support from UCB and Novartis. BWK has received research support from Eli Lilly, Novartis and UCB Pharma. He has been an advisor or received speaker fees from Abbvie, Eli-Lilly, Gilead, Janssen and Novartis. The authors have no additional financial interests to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}],"article-number":"40"}}